

Andrew Galazka - Biography

(April 29, 2025)



Dr Andrew Galazka is a highly experienced, medically qualified pharmaceutical executive who has worked in senior management/ board level roles for a variety of biotech and pharmaceutical companies. Following his medical studies at Cambridge University and postgraduate medical training in the UK, he has worked in the global biopharmaceutical industry for over 35 years (Biogen, GlaxoSmithKline, Serono, Merck Serono). Following his recent retirement from Merck Serono he is now an independent board member/ senior advisor to the industry. He lectures on drug development of pharmaceutical and biopharmaceutical products on the postgraduate Management of Life Sciences course at the EPFL (the Swiss Federal Institute of Technology) in Lausanne.

He has been a board member at Axovan (which was sold to Actelion), Addex, a company specialized in allosteric modulation (successfully listed on the Swiss Stock Exchange). He was also a board member of Serono Europe, which was responsible for all of Serono's interactions with the EMA for over 20 years. He was scientific advisor to the award winning Neomed IV venture capital fund. He is currently an Independent Board Member at MedXCell a Swiss biotech venture builder. He is also an Independent Board Member and interim Chief Medical Officer at CyteaBio, a French/Swiss start-up. This is a company specialized in arming allogeneic effector cells with monoclonal antibodies. The first product is due to enter clinical testing in oncology (glioblastoma multiforme) in early 2026.

A seasoned leader, he has a strong track record of leadership in large and small company environments. He has extensive senior management experience in Drug Development, especially clinical development and regulatory strategy. He successfully led drug development programs through to regulatory approval/ launch in a wide variety of therapeutic areas including autoimmune & inflammatory diseases, oncology, neurology, endocrinology, infectious & tropical diseases, and dermatology. He was responsible for the development of several high-profile products throughout his career, several of which

became blockbusters and has extensive experience of scientific interactions with key regulatory authorities around the world (principally US, EU, Switzerland, Canada, Australia, Japan). At Merck Serono he was awarded the Merck 350-Year Anniversary Award by CEO, Belen Garijo for heading up the global development renaissance of Mavenclad, regarded by many analysts as an impossible prospect, but now transformed into a blockbuster in the treatment of multiple sclerosis. At Serono he won the “Centurion” CEO Award (awarded by Ernesto Bertarelli) for his leadership excellence in drug development.

As head of Global Strategic Marketing in New Therapeutic Areas at Serono/ Merck Serono for several years he was responsible, among other things, for masterminding the company’s entry into oncology and the selection of the anti-PD-L1 monoclonal antibody, *avelumab* (a check point inhibitor), now known as Bavencio, as the company’s focus for development in the oncology field.

He made a major contribution to the corporate development of Serono through his senior leadership roles in Development and Strategic Marketing. In addition, for a 3-year period at Serono he was also SVP of Investor Relations and Scientific Affairs. Working closely with the CEO and CFO, he spear-headed Serono’s listing on the New York Stock Exchange, thus raising over \$2 billion from institutional investors and resulting in a tripling of the Company’s valuation. Together with his team, he was ranked first by Thomson-Extel for biotechnology investor relations based on a survey of European buy-side and sell-side analysts.

Education

Dr Galazka earned his medical doctor degree (with distinction) from Cambridge University following a master’s degree in pathology and pharmacology. Following clinical practice, he specialized in pharmaceutical medicine in both the UK (Royal College of Physicians) and Switzerland (FMH). He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK).

Other information

Nationality : British and Swiss

Languages : English, French, Polish